
Haloperidol - Schizophrenia and other psychoses
You are here : Home > Formulary Search > Haloperidol - Schizophrenia and other psychoses
Status 1
- Oral solution
- Tablets
Off-label use.
Initiation by a SABP specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.
Status 2
- Capsules
Capsules are an unlicensed product.
Initiation by a SABP specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.
Status 3
- Depot injection
Haloperidol decanoate - administration under the shared-care LCS when prescribed in Primary Care.
See shared care document below
Status 4
- Depot injection
Haloperidol decanoate - where there is no LCS in place, the prescribing responsibility remains with SABP.
Secondary Care may prescribe for in-patients (on the instruction of a SABP specialist) and prescribing continued by SABP after discharge.
Documentation
- No records returned.
PAD Profile
Other Indications
Below are listed other indications that Haloperidol is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Schizophrenia and other psychoses.
Committee Recommendations (1)
The Surrey Heartlands APC recommends the administration of depot antipsychotic injections under an AMBER shared care agreement for practices that have signed up to the agreed locally commissioned service (LCS).
The updated shared care agreement can be found below.
Surrey Heartlands CCG have developed the LCS to enable stable patients with schizophrenia to be prescribed and administered these injections through their primary care prescriber (GP).
If a practice has not signed up to the LCS the drug remains as RED status and prescriptions will be issued by the provider.